Skip to main content

Table 4 Treatment-related adverse events of special interest, by the outcome and action taken

From: Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study

Treatment-related adverse events of special interest

Number of events

Outcome, n (%)

Action taken, n (%)

Resolved

Improved

Persistent

Led to death

Unknown

Temporary interruption

Dose reduction

Permanent discontinuation

Hypertension

1582

895 (57%)

221 (14%)

449 (28%)

0

17 (1%)

84 (5%)

39 (2%)

15 (1%)

Proteinuria

933

477 (51%)

95 (10%)

353 (38%)

0

8 (1%)

112 (12%)

31 (3%)

22 (2%)

Hand-foot syndrome

400

205 (51%)

55 (14%)

139 (35%)

0

1 (< 1%)

98 (25%)

36 (9%)

15 (4%)

Bleeding

784

477 (61%)

39 (5%)

227 (29%)

27 (3%)

14 (2%)

75 (10%)

10 (1%)

83 (11%)

Hepatotoxicity

1464

616 (42%)

147 (10%)

658 (45%)

6 (< 1%)

37 (3%)

105 (7%)

21 (1%)

55 (4%)

Cardiac toxicity

56

36 (64%)

3 (5%)

17 (30%)

0

0

10 (18%)

0

2 (4%)

  1. Percentages are based on the total number of events in each category